ATE333874T1 - Konjugierte linolensäure zur behandlung von cyclooxygenase-2 vermittelten entzündungen und schmerzen - Google Patents

Konjugierte linolensäure zur behandlung von cyclooxygenase-2 vermittelten entzündungen und schmerzen

Info

Publication number
ATE333874T1
ATE333874T1 AT00916646T AT00916646T ATE333874T1 AT E333874 T1 ATE333874 T1 AT E333874T1 AT 00916646 T AT00916646 T AT 00916646T AT 00916646 T AT00916646 T AT 00916646T AT E333874 T1 ATE333874 T1 AT E333874T1
Authority
AT
Austria
Prior art keywords
cyclooxygenase
pain
treatment
linolenic acid
mediated inflammation
Prior art date
Application number
AT00916646T
Other languages
English (en)
Inventor
Mark E Cook
Leah D Whigham
Michael W Pariza
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE333874T1 publication Critical patent/ATE333874T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT00916646T 1999-07-20 2000-03-24 Konjugierte linolensäure zur behandlung von cyclooxygenase-2 vermittelten entzündungen und schmerzen ATE333874T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/357,268 US6077868A (en) 1999-07-20 1999-07-20 Selective inhibition of cyclooxygenase-2

Publications (1)

Publication Number Publication Date
ATE333874T1 true ATE333874T1 (de) 2006-08-15

Family

ID=23404937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916646T ATE333874T1 (de) 1999-07-20 2000-03-24 Konjugierte linolensäure zur behandlung von cyclooxygenase-2 vermittelten entzündungen und schmerzen

Country Status (8)

Country Link
US (1) US6077868A (de)
EP (1) EP1196161B1 (de)
AT (1) ATE333874T1 (de)
AU (1) AU3772000A (de)
CA (1) CA2379649C (de)
DE (1) DE60029591T2 (de)
ES (1) ES2269122T3 (de)
WO (1) WO2001005395A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
JP2003506324A (ja) * 1999-07-09 2003-02-18 ファルマシア・コーポレイション 共役脂肪酸化合物を用いるシクロオキシゲナーゼ−２媒介障害の治療
EP1097708B1 (de) * 1999-11-02 2003-09-17 Loders Croklaan B.V. Verwendung von trans-trans-Isomeren von konjugierter Linolsäure
EA008242B1 (ru) * 1999-12-08 2007-04-27 Фармация Корпорейшн Композиции на основе ингибитора циклооксигеназы-2 с быстро наступающим терапевтическим действием и способы лечения заболеваний
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
US7365099B2 (en) 2001-05-31 2008-04-29 Wisconsin Alumni Research Foundation Animal body fat control
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
DE60332387D1 (de) 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050014832A1 (en) * 2003-07-16 2005-01-20 Lc Usa Llc Treatment
DE10332712A1 (de) * 2003-07-18 2005-02-10 Cognis Deutschland Gmbh & Co. Kg Verwendung von c9,t11-Isomeren der konjugierten Linolsäure
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
US20050154059A1 (en) * 2004-01-13 2005-07-14 Cook Mark E. Method of treating type III hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid
JP2007518788A (ja) 2004-01-22 2007-07-12 ファイザー・インク バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
CA2563963A1 (en) * 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
US20070281044A1 (en) * 2006-06-02 2007-12-06 Mueller Mark J Use of cold-pressed edible seed oils, flours, and/or blends thereof as anti-inflammatory and cox-2 inhibitory agents
ATE511860T1 (de) 2006-12-22 2011-06-15 Recordati Ireland Ltd Kombinationstherapie für erkrankungen der unteren harnwege mit 2 liganden und nsar
CN109906082A (zh) 2016-09-07 2019-06-18 塔夫茨大学信托人 使用免疫dash抑制剂和pge2拮抗剂的组合治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434101A (en) * 1981-09-14 1984-02-28 Hoffmann-La Roche Inc. Inhibitors of SRS-synthesis
US5070104A (en) * 1989-02-17 1991-12-03 Wisconsin Alumni Research Foundation Methods of chelating metal and novel compositions therefor
US5017614A (en) * 1989-02-17 1991-05-21 Wisconsin Alumni Research Foundation Methods of preventing oxidation, quenching singlet oxygen and inhibiting mold growth and novel compositions therefor
US5554646A (en) * 1992-04-29 1996-09-10 Wisconsin Alumni Research Foundation Method for reducing body fat in animals
US5430066A (en) * 1992-04-29 1995-07-04 Wisconsin Alumni Research Foundation Methods for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation
US5428072A (en) * 1992-04-29 1995-06-27 Wisconsin Alumni Research Foundation Method of increasing the efficiency of feed conversion in animals
US5760082C1 (en) * 1994-08-29 2001-03-06 Wisconsin Alumni Res Found Dietetic foods containing conjugated linoleic acids
US5747537A (en) * 1995-09-05 1998-05-05 Washington University Method of inhibiting parasitic activity
US5585400A (en) * 1996-02-27 1996-12-17 Wisconsin Alumni Research Foundation Methods of attenuating the allergic response in animals
AU5104198A (en) * 1996-11-05 1998-05-29 Wisconsin Alumni Research Foundation Use of conjugated linoleic acid to enhance natural killer lymphocyte function
US5851572A (en) * 1997-04-25 1998-12-22 Wisconsin Alumni Research Foundation Method of increasing fat firmness and improving meat quality in animals with conjugated linolenic acid
EP1041979A4 (de) * 1997-12-23 2001-10-04 Dcv Inc Ester von konjugierter linolsäure oder konjugierter linolensäure und deren verwendung
US6077525A (en) * 1998-04-10 2000-06-20 The George Washington University Use of conjugated linoleic acids

Also Published As

Publication number Publication date
AU3772000A (en) 2001-02-05
DE60029591T2 (de) 2007-08-09
ES2269122T3 (es) 2007-04-01
CA2379649C (en) 2009-03-10
WO2001005395A1 (en) 2001-01-25
EP1196161A1 (de) 2002-04-17
EP1196161B1 (de) 2006-07-26
US6077868A (en) 2000-06-20
DE60029591D1 (de) 2006-09-07
CA2379649A1 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
DE60029591D1 (de) Konjugierte linolensäure zur behandlung von cyclooxygenase-2 vermittelten entzündungen und schmerzen
DE69613840D1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
DE69736745D1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
ATE223213T1 (de) Konjugierte linoleinsäure zur erhaltung oder erhöhung des knochenmineraliengehaltes
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE60212964D1 (de) Zusammensetzungen zur behandlung von tierischen krankheiten und syndromen mit transferfaktor
ATE221377T1 (de) Verfahren zur reduzierung der körperfettanteils bei tieren mit der verabreichungvon konjugiergter linolsäure
ATE356113T1 (de) Probucolbernsteinsäureester zur hemmung der expression von vcam-1
DE69412807D1 (de) Einrichtung zur abgabe von elektrischen impulsen für die behandlung biologischer gewebe
ATE54823T1 (de) Mittel und verfahren zur erzielung einer oertlichen gewichtsabnahme.
DK0918516T3 (da) Fremgangsmåde til forebyggelse af skeletale problemer hos fjerkræ
DE60142712D1 (de) Verwendung von Botulinum Toxin zur Behandlung von Eingweideschmerzen
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE369871T1 (de) Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten
NO20015122L (no) Behandling av fibrose ved anvendelse av en antagonist for integrin <alfa>-4-subenheten
DE60234873D1 (de) Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen
ATE310511T1 (de) Verwendung von konjugierten linoleinsäure zur behandlung von type ii diabetes
ATE311871T1 (de) Verwendung von zinksalzen der konjugierten linoleinsäuren zur behandlung von hautkrankheiten
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE69632396D1 (de) Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
FI972004A7 (fi) Implantoitava laite vaikuttavien aineiden antamiseen kasveille
DE60022478D1 (de) Verwendung des vaskularen endothelialen wachstumsfaktors zur behandlung von erektilen dysfunktionen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE90563T1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties